Global Acute Intermittent Porphyria Therapeutics Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Acute Intermittent Porphyria Therapeutics Market Insights, Forecast to 2034
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
Market Analysis and InsightsGlobal Acute Intermittent Porphyria Therapeutics Market
Global Acute Intermittent Porphyria Therapeutics market is expected to reach to US$ 50 million in 2023, with a positive growth of %, compared with US$ 49 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Acute Intermittent Porphyria Therapeutics industry is evaluated to reach US$ 56 million in 2033. The CAGR will be 1.8% during 2023 to 2033.
Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
Report Covers
This report presents an overview of global Acute Intermittent Porphyria Therapeutics market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Acute Intermittent Porphyria Therapeutics market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Recordati Rare Diseases
Segment by Type
350mg
313mg
Hospital
Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Acute Intermittent Porphyria Therapeutics introduction, etc. Acute Intermittent Porphyria Therapeutics Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Acute Intermittent Porphyria Therapeutics
Chapter 13Methodology and Data Sources adopted by MRAResearch
Market Analysis and InsightsGlobal Acute Intermittent Porphyria Therapeutics Market
Global Acute Intermittent Porphyria Therapeutics market is expected to reach to US$ 50 million in 2023, with a positive growth of %, compared with US$ 49 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Acute Intermittent Porphyria Therapeutics industry is evaluated to reach US$ 56 million in 2033. The CAGR will be 1.8% during 2023 to 2033.
Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
Report Covers
This report presents an overview of global Acute Intermittent Porphyria Therapeutics market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Acute Intermittent Porphyria Therapeutics market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Recordati Rare Diseases
Segment by Type
350mg
313mg
Segment by Application
Hospital
Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Acute Intermittent Porphyria Therapeutics introduction, etc. Acute Intermittent Porphyria Therapeutics Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Acute Intermittent Porphyria Therapeutics
Chapter 13Methodology and Data Sources adopted by MRAResearch
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices